News
News from us and our partners
News
Capital
News
Biovelocita
News
Crossover
News
Capital
News
Sofinnova Partners closes €650M ($750M) Capital XI, greatly exceeding initial target to back early-stage healthcare deals
Sofinnova Partners exceeds target with €165M biotech acceleration fund, Europe’s largest, with strong Pharma support
CEO spotlight: Thierry Abribat's third straight win
Johnson & Johnson to acquire Shockwave Medical
CEO spotlight: CinCor's Marc de Garidel
Tags
Topics
0 results
- News
T-Therapeutics announces Series A extension to $91 million to advance first-in-class bispecifics towards the clinic
- News
Inventiva announces pricing of upsized public offering of approximately $150M American Depositary Shares
- News
Qorium Secures €22m Investment to Accelerate Cultivated Leather Commercialisation
- News
Muna Therapeutics Announces First Subjects Dosed in Phase 1 Trial of Novel Oral TREM2 Agonist for Early Alzheimer’s Disease
- News
Noema Pharma Announces Phase 2a Study Results with Cendifensine in Women with Vasomotor Symptoms (Hot Flashes) Due to Menopause
- News
Tulyp Medical emerges from Sofinnova’s medtech accelerator and announces FDA submission following initial first-in-human use
- News
Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis
- News
AAVantgarde Closes $141 Million Series B Financing
- News
Hemab Therapeutics Announces $157 Million Series C Financing to Advance Next-Generation Treatments for Underserved Bleeding Disorders
- News
Elevara Medicines Raises $70 Million Series A to Advance Phase 2 Rheumatoid Arthritis Trial and Expand Pipeline
- News
Mission Therapeutics raises $13.3 million to progress first-in-class Parkinson’s disease candidate MTX325 through clinical trials
- News
Verley becomes first company to receive FDA "No Questions Letter" for functionalized dairy Proteins made via precision fermentation
- News
NanoPhoria Bioscience secures €83.5 Million Series A to advance breakthrough heart failure therapy and expand portfolio for novel Nano-in-Micro delivery platform
- News
AAVantgarde Announces FDA Orphan Drug Designation and UK CTA approval for AAVB-039 for the Treatment of Stargardt Disease
- News
Sitryx receives FDA clearance of IND application for SYX-5219 for the treatment of atopic dermatitis